TY - JOUR
T1 - Insights into the interplay between KIR gene frequencies and chronic HBV infection in Burkina Faso
AU - Sorgho, Pegdwendé Abel
AU - Martinson, Jeremy James
AU - Djigma, Florencia Wendkuuni
AU - Yonli, Albert Théophane
AU - Nagalo, Bolni Marius
AU - Compaore, Tegwinde Rebeca
AU - Obiri-Yeboah, Dorcas
AU - Diarra, Birama
AU - Sombie, Herman Karim
AU - Zongo, Arsène Wendpagnangdé
AU - Ouattara, Abdoul Karim
AU - Soubeiga, Serge Théophile R.
AU - Traore, Lassina
AU - Roberts, Lewis R.
AU - Simpore, Jacques
N1 - Publisher Copyright:
© 2018 Universita Cattolica del Sacro Cuore. All Rights Reserved.
PY - 2018
Y1 - 2018
N2 - Background/Objective: Hepatitis B virus (HBV) infection is the leading risk factor for cirrhosis and hepatocellular carcinoma (HCC).The objective of this investigation was to assess the association between "Killer Cell Immunoglobulin-Like Receptor" (KIR) gene frequencies and chronic HBV infection. Methods: Chronic HBV carriers and healthy patients were selected for this study. The viral load for HBV were performed, and SSP-PCR was used to characterize the frequencies of KIR genes. Results: The study suggested that inhibitory genes KIR2DL2 (crude OR = 2.82; p 0.001), KIR2DL3 (crude OR = 2.49; p 0.001) and activator gene KIR2DS2 (crude OR = 3.95; p 0.001) might be associated with chronic stages of HBV infection. Conversely the inhibitory genes KIR3DL1 (crude OR = 0.49; p = 0.0018) and KIR3DL2 (crude OR = 0.41; p = 0.005), the activator gene KIR2DS1 (crude OR = 0.48; p = 0.014) and the pseudo gene KIR2DP1 (crude OR = 0.49; p = 0.008) could be associated with immunity against HBV infection. Chronic HBV patients who are carriers for the KIR3DL3 gene (crude OR = 8; p = 0.048) were positive for HBeAg and patients who carried the KIR3DL2 gene (crude OR = 3.21; p = 0.012) had a high HBV viral load compared to the rest of the study population. Conclusion: Our data showed evidence of a correlation between the risk of developing chronic HBV infection and certain KIR gene frequencies and also show that KIR3DL1, KIR3DL2, KIR2DS1 might confer a protective status against chronic HBV infection.
AB - Background/Objective: Hepatitis B virus (HBV) infection is the leading risk factor for cirrhosis and hepatocellular carcinoma (HCC).The objective of this investigation was to assess the association between "Killer Cell Immunoglobulin-Like Receptor" (KIR) gene frequencies and chronic HBV infection. Methods: Chronic HBV carriers and healthy patients were selected for this study. The viral load for HBV were performed, and SSP-PCR was used to characterize the frequencies of KIR genes. Results: The study suggested that inhibitory genes KIR2DL2 (crude OR = 2.82; p 0.001), KIR2DL3 (crude OR = 2.49; p 0.001) and activator gene KIR2DS2 (crude OR = 3.95; p 0.001) might be associated with chronic stages of HBV infection. Conversely the inhibitory genes KIR3DL1 (crude OR = 0.49; p = 0.0018) and KIR3DL2 (crude OR = 0.41; p = 0.005), the activator gene KIR2DS1 (crude OR = 0.48; p = 0.014) and the pseudo gene KIR2DP1 (crude OR = 0.49; p = 0.008) could be associated with immunity against HBV infection. Chronic HBV patients who are carriers for the KIR3DL3 gene (crude OR = 8; p = 0.048) were positive for HBeAg and patients who carried the KIR3DL2 gene (crude OR = 3.21; p = 0.012) had a high HBV viral load compared to the rest of the study population. Conclusion: Our data showed evidence of a correlation between the risk of developing chronic HBV infection and certain KIR gene frequencies and also show that KIR3DL1, KIR3DL2, KIR2DS1 might confer a protective status against chronic HBV infection.
KW - Burkina Faso
KW - Chronic hepatitis B
KW - HBV
KW - KIR
UR - http://www.scopus.com/inward/record.url?scp=85060976411&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060976411&partnerID=8YFLogxK
U2 - 10.4084/MJHID.2018.060
DO - 10.4084/MJHID.2018.060
M3 - Article
AN - SCOPUS:85060976411
SN - 2035-3006
VL - 10
JO - Mediterranean Journal of Hematology and Infectious Diseases
JF - Mediterranean Journal of Hematology and Infectious Diseases
IS - 1
M1 - e2018060
ER -